• Adagene broadened its strategic licensing collaboration with Third Arc Bio after Third Arc selected the first lead masked CD3 T cell engager.
• Third Arc will sponsor and fund clinical development under revised terms that shift the deal toward an integrated asset and technology partnership.
• Total potential payments to Adagene increased, including development milestones and commercial milestones.
• Adagene retained a no-cost option to develop and commercialize the candidates in Greater China, Singapore, South Korea.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-106554), on September 10, 2026, and is solely responsible for the information contained therein.